Dupilumab
R668-AD-1652
Approved small_molecule active
Quick answer
Dupilumab for Dermatitis, Atopic is a Approved program (small_molecule) at Regeneron UK Limited with 5 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Dermatitis, Atopic
- Phase
- Approved
- Modality
- small_molecule
- Status
- active